Last reviewed · How we verify
SAL-0951
SAL-0951 is a small molecule inhibitor targeting a specific molecular pathway involved in disease pathogenesis.
At a glance
| Generic name | SAL-0951 |
|---|---|
| Also known as | SAL-0951 group |
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed mechanism information, SAL-0951's exact molecular target and pathway remain unclear. As a Phase 3 asset from Shenzhen Salubris Pharmaceuticals, it is undergoing late-stage clinical development, but comprehensive mechanistic data has not been widely disclosed in accessible literature.
Approved indications
Common side effects
Key clinical trials
- SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies (PHASE2)
- Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis (PHASE3)
- Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis (PHASE3)
- SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |